Opinion|Videos|September 5, 2024
Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do head-to-head data affect your treatment decisions?
- What does consistency of remission across patient types mean to you?
How often do you rely on remission data when considering switching therapies?
Advertisement
Related to this article
Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.
The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.
An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.
In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.
RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.
In a matched claims analysis, 94% of patients with PMR initiating sarilumab discontinued glucocorticoids by 12 months vs 78% initiating methotrexate.
Patients with relapsing GCA who stopped upadacitinib after year 1 flared sooner and needed far more glucocorticoids than new-onset patients.
In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH
5